Dolasetron Mesylate — Veterinary Vademecum Drug Reference

Dosage & Administration Guidelines

Species	Route	Dose	Frequency	Duration & Clinical Notes
Dog	IV	0.6 mg/kg	Once daily	Duration: As needed, typically 1-5 days Notes: Administer slowly over 1-2 minutes. May be used for prevention of chemotherapy-induced vomiting.
Dog	PO	1-2 mg/kg	Once daily	Duration: As needed, typically 1-5 days Notes: For treatment of acute vomiting. Can be given with or without food.
Cat	IV	0.6 mg/kg	Once daily	Duration: As needed, typically 1-5 days Notes: Administer slowly. Use with caution in cats with hepatic or renal impairment.
Cat	PO	1-2 mg/kg	Once daily	Duration: As needed, typically 1-5 days Notes: For treatment of acute vomiting. May be used for chemotherapy-induced emesis.
Horse	Not applicable	Not established	Not established	Duration: Not established Notes: Not commonly used in horses; no established dosage.
Cattle	Not applicable	Not established	Not established	Duration: Not established Notes: Not commonly used in cattle; no established dosage.

Clinical Indications & Species Uses

General Indications

Prevention and treatment of nausea and vomiting
Management of chemotherapy-induced emesis

Dog (Canine)

Prevention and treatment of acute vomiting
Vomiting associated with chemotherapy
Vomiting associated with motion sickness
Vomiting due to gastroenteritis
Postoperative nausea and vomiting

Cat (Feline)

Prevention and treatment of acute vomiting
Vomiting associated with chemotherapy
Vomiting due to gastroenteritis
Postoperative nausea and vomiting

Pharmacology & Mechanism of Action

Drug Class: Antiemetic | Pharmacological Group: 5-HT3 receptor antagonist

Mechanism of Action: Dolasetron is a selective 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist. Its active metabolite, hydrodolasetron, binds to 5-HT3 receptors located on vagal afferent neurons in the gastrointestinal tract and in the chemoreceptor trigger zone (CTZ) of the central nervous system. By blocking these receptors, dolasetron inhibits the emetic reflex triggered by chemotherapy, radiation, toxins, or other stimuli. It has minimal affinity for other serotonin receptors, dopamine receptors, or adrenergic receptors, which contributes to its favorable side effect profile.

Pharmacodynamics: Dolasetron reduces the incidence and severity of vomiting and nausea by antagonizing 5-HT3 receptors. It is effective against both centrally and peripherally mediated emesis. The onset of action is rapid, and the duration of effect is dose-dependent. In veterinary patients, it is used primarily for prevention and treatment of acute vomiting, especially associated with chemotherapy, motion sickness, and gastroenteritis. It does not have significant anti-inflammatory or analgesic properties.

⚡ Pharmacokinetics Summary

Absorption: Dolasetron is rapidly and well absorbed after oral administration. In dogs, oral bioavailability is approximately 70-80%. The active metabolite hydrodolasetron is formed quickly, and peak plasma concentrations are reached within 1-2 hours. In cats, absorption is also rapid, with peak levels occurring within 1-2 hours.

Distribution: Hydrodolasetron is widely distributed throughout the body. The volume of distribution is approximately 2-3 L/kg in dogs. It crosses the blood-brain barrier to a limited extent, but sufficient concentrations are achieved in the CTZ to exert antiemetic effects. Protein binding of hydrodolasetron is approximately 50-60% in dogs and cats.

Metabolism: Dolasetron is extensively metabolized in the liver, primarily by cytochrome P450 enzymes (CYP2D6 in humans, but in dogs and cats, specific isoenzymes are less well defined). The primary metabolic pathway is reduction of the ketone group to form hydrodolasetron, which is the active moiety. Further metabolism includes hydroxylation and conjugation.

Excretion: Hydrodolasetron and its metabolites are excreted primarily in the urine (approximately 60-70%) and feces (approximately 20-30%). In dogs, the elimination half-life of hydrodolasetron is approximately 7-8 hours. In cats, the half-life is slightly longer, around 8-10 hours.

Half-Life: Dogs: 7-8 hours (hydrodolasetron); Cats: 8-10 hours (hydrodolasetron)

Bioavailability: Oral: ~70-80% in dogs; ~60-70% in cats

Protein Binding: Approximately 50-60% in dogs and cats

Available Formulations & Strengths

Oral Tablet 50 mg, 100 mg (PO)

Injectable Solution 20 mg/mL (2 mL vials) (IV)

Contraindications & Clinical Warnings

Contraindications:

Known hypersensitivity to dolasetron or any component of the formulation
Patients with pre-existing cardiac conduction abnormalities (e.g., QT prolongation, heart block)
Concurrent use with other drugs that prolong QT interval (e.g., certain antiarrhythmics, macrolide antibiotics, fluoroquinolones) due to risk of additive QT prolongation

Warnings & Clinical Precautions:

Use with caution in patients with hepatic or renal impairment, as drug clearance may be reduced.
Monitor for signs of QT prolongation, especially in patients with electrolyte imbalances (e.g., hypokalemia, hypomagnesemia) or those receiving other QT-prolonging drugs.
In dogs, rare cases of cardiac arrhythmias have been reported; use with caution in patients with pre-existing cardiac disease.
Safety in pregnant or lactating animals has not been fully established; use only when clearly needed.
Do not administer intra-arterially; for IV use, inject slowly to avoid hypotension.
In cats, may cause transient hypotension when given IV; monitor blood pressure during administration.

Adverse Effects & Reactions

Common:

Mild sedation
Diarrhea
Headache (in humans, but not typically observed in animals)
Injection site reactions (pain, swelling)

Serious / Severe:

QT interval prolongation
Cardiac arrhythmias (e.g., ventricular tachycardia, torsades de pointes)
Hypotension (especially with rapid IV administration)
Seizures (rare)

Rare:

Allergic reactions (urticaria, angioedema)
Hepatotoxicity (elevated liver enzymes)
Extrapyramidal effects (dystonia, dyskinesia)

Key Drug Interactions

Interacting Drug / Class	Clinical Effect & Mechanism	Severity
QT-prolonging drugs (e.g., amiodarone, sotalol, erythromycin, clarithromycin, fluoroquinolones)	Additive QT prolongation, increasing risk of serious cardiac arrhythmias.	High
Diuretics (e.g., furosemide)	May cause electrolyte imbalances (hypokalemia, hypomagnesemia), which can increase the risk of QT prolongation.	Moderate
Corticosteroids	May increase the risk of gastrointestinal ulceration when used concurrently, though not a direct interaction with dolasetron.	Mild
Anticholinergic drugs (e.g., atropine)	May enhance the anticholinergic effects, though not clinically significant.	Mild

Overdose & Toxicity Management

Signs of Toxicity:

Severe QT prolongation
Ventricular arrhythmias
Hypotension
Sedation
Tremors
Seizures

Emergency Treatment Protocol: There is no specific antidote for dolasetron overdose. Treatment is symptomatic and supportive. In cases of recent oral ingestion, gastric lavage or administration of activated charcoal may be considered. Monitor cardiac function with ECG, and treat arrhythmias with appropriate antiarrhythmic agents (e.g., lidocaine for ventricular arrhythmias). Correct electrolyte imbalances (potassium, magnesium) as needed. Provide intravenous fluids to support blood pressure. In severe cases, consider referral to a veterinary emergency facility.

Food Animal Withdrawal Times

Dolasetron is not approved for use in food-producing animals. If used off-label in food animals, a withdrawal time of at least 30 days for meat and 7 days for milk is recommended, but this is not officially established. Consult with a veterinary pharmacologist for specific guidance.

Storage, Handling & Regulatory Information

Storage Temperature: Store at controlled room temperature 20-25°C (68-77°F); excursions permitted between 15-30°C (59-86°F).

Light Sensitivity: Light-sensitive — protect from direct exposure.

Handling & Special Conditions: Protect from light. Keep in a tightly closed container. Do not freeze the injectable solution.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Not FDA-approved for veterinary use; approved for human use (Anzemet) but not marketed in some countries. In veterinary medicine, it is used off-label.

Extra-Label (Off-Label) Use: In the United States, dolasetron is not FDA-approved for veterinary use, but it may be used legally under the Animal Medicinal Drug Use Clarification Act (AMDUCA) in an extra-label manner by or on the order of a licensed veterinarian, provided that appropriate withdrawal times are observed for food animals.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Dolasetron mesylate is a potent 5-HT3 receptor antagonist used in veterinary medicine primarily for the management of acute vomiting, especially that induced by chemotherapy. It is generally well tolerated, but its use requires caution in patients with cardiac disease or those receiving other QT-prolonging drugs. The active metabolite hydrodolasetron is responsible for the antiemetic effect, and the drug has a relatively long half-life, allowing once-daily dosing. In dogs and cats, the oral route is convenient for outpatient therapy, while the injectable form is useful for hospitalized patients or when rapid onset is needed. Although not approved for veterinary use, it is a valuable option in the antiemetic armamentarium. Always consider the underlying cause of vomiting and provide supportive care as needed. Monitor for adverse effects, particularly cardiac effects, in high-risk patients.

References & Literature

📚 Plumb's Veterinary Drug Handbook
📚 Papich Veterinary Pharmacology and Therapeutics
📚 Compendium of Veterinary Products (CVP)